Synthego raises $100 million for AI-driven gene editing
Summary
Synthego, which is developing a machine learning-based approach to engineering genomes, today closed a $100 million funding round. The startup says the funding will be put toward expanding the capabilities of its platforms designed to produce reagents and cells supporting basic research and clinical trials. That’s one of the reasons gene therapies like Novartis’ Zolgensma, a treatment for Spinal Muscular Atrophy (SMA), cost in excess of hundreds of thousands of dollars per patient. The company says it exceeds the capabilities of similar products from rivals like General Electric, shortening the work of scientists from weeks to days. In the near term, the company plans to further develop its CRISPR kits that create different genetic lines based on requests from researchers and its commercial products that produce clinical-grade materials for trials on living subjects.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
